This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use.
I accept
News & Events
News | June 10, 2022
Prof. Dr. Petr Lokhov, CEO of Biobohemia, was invited by the journal "Pharmaceutics" as a Guest Editor of the Special Issue "Cancer Vaccine Technologies: Current Progress and Future Perspectives"
Cancer vaccine experts are invited to contribute to this special issue. Original research papers, communications, and review papers will be considered for publication.
PRESS RELEASE / CAMBRIDGE, May 10, 2022
Biobohemia Pushes Forward Antigenic Essence Technology in Released Paper
Biobohemia's scientists share in a released paper the experience gained over the past year in advancing antigenic essence technology, including that related to relationships with contract manufacturing organizations, the upgrading of existing experimental cancer vaccines, and the legal and ethical aspects of the technology.
Publication
Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions
We are pleased to announce the release of our new scientific paper, which reveals the full potential of Biobohemia's Antigenic Essence technology platform and its prospects for cancer vaccines development.
Event | January 10-13, 2022
Bioboemia participated in 40th Annual J.P. Morgan Healthcare Conference (JPM 2022)
This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
News | December 08, 2021
Special report: "5 High-Impact Cancer Vaccine Platforms"
Antigenic Essence technology platform was included in special report "5 High-impact Cancer Vaccine Platforms" released by Deep Pharma Intelligence. The report profiles the ecosystem of cancer vaccines companies on the cutting-edge of the field, and identify research strategies and platforms for cancer vaccine development holding the greatest potential to lead to breakthrough innovations in the coming years.
Webinar | November 23, 2021
The Landscape of Cancer Vaccines and Research Platforms: The Cutting Edge
Biobohemia will take part in the webinar organized by Deep Pharma Intelligence and present its scientific approach to the development of cancer vaccines, as well as share the nearest business plans and growth strategies.
Article | May 25, 2021
The Search for a Cancer Vaccine: Have We Been Doing It All Wrong?
Can the surface of a cancer cell shed light on how to develop effective cancer vaccines? Biobohemia, Inc. uses their "Antigenic Essence technology" to find out. Article by Robin Seaton Jefferson at SynBioBeta.
News | April 2, 2021 (Science X)
Cancer Vaccines are Revitalized by Antigenic Essence Technology
In this article we introduce readers to antigenic essence technology, omitting some technical aspects and allowing certain liberties in the interpretation of scientific facts in favor of a reader-friendly narrative.
PRESS RELEASE / BOSTON, March 17, 2021
Biobohemia Released Paper on the Discovery of the Antigenic Essence of Cancer Cells
Scientists announced today that they have discovered why they have not succeeded in developing a vaccine against cancer. According to scientists at BioBohemia, the answer lies on the surface.
Publication
Antigenic Essence: Upgrade of Cellular Cancer Vaccines
Cancer vaccine technologies have been expanded with a new direction - ANTIGENIC ESSENCE technology by Biobohemia, which allows updating already developed cellular vaccines, as well as developing new ones.
Publication
SANTAVACTM: Summary of Research and Development
Here is our latest scientific paper, which summarizes all the R&D on our main product SANTAVACTM.